Log ind
Jan van de Winkel4.jpg
Foto: Stine Bidstrup

”A drug like Darzalex only comes along once every 20 years”

Top picks in English:

Genmab’s CEO is ecstatic over the biotech's “shining star”, bone marrow cancer drug Darzalex. He doubts he will see anything like it in his time in the company, but is working intently on finding a new cash cow.


BY LOUISE WENDT JENSEN
Offentliggjort 28.02.17 kl. 16:22

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Sanofi predicts digital revolution of diabetes care

555001.jpg Top picks in English:

A more digitalized therapy will benefit both diabetes patients and the healthcare systems’ economy, says Sanofi’s global heads of Diabetes Reseach and Integrated Care. The company wants to be at the forefront of the digital revolution, in part through a major partnership with the Google company Verily.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

GN sees progress for troubled US unit

Top picks in English:

The Danish hearing device giant GN Hearing has experienced Q1 growth rates unseen in years at the US subsidiary Beltone, says chief executive Anders Hedegaard. Beltone is crucial for GN’s growth in the US, estimates senior analyst.

Dako CEO to resign

Top picks in English:

A change in the corporate structure means the CEO of Danish diagnostics firm Dako, a former Novo Nordisk VP, is stepping down from her position.

Novo invests millions in new NASH player

Top picks in English:

Novo Ventures has taken the lead in a Series A financing round in a new US-based company developing medicine against the liver disease NASH – a disease that big as well as small companies have started to focus on, including Novo Nordisk.

Forsiden lige nu

Amerikansk medicokoncern fortsætter dansk vækst

REGNSKAB.jpg Medico & Rehab:

Edwards Lifesciences A/S kan endnu engang fremvise vækst på alle vigtige parametre, fremgår det af selskabets årsregnskab 2016.

Coloplast-chef scorer gevinst på 27 mio efter aktiesalg

Medico & Rehab:

Coloplasts topchef Lars Rasmussen kan efter salget af 100.000 aktier lægge en større formue i lommen.

Merck-middel får FDA-genvej mod mavekræft

Medicinal & Biotek:

Indikationsudvidelserne ser ud til at kunne fortsætte for Mercks kræftblockbuster Keytruda, som nu har fået en regulatorisk smutvej til det amerikanske marked inden for behandling af mavekræft.

Ny topchef ryster posen hos presset biotekselskab

Medicinal & Biotek:

Der er kommet en ny mand på topposten hos Alexion, som har været en hård periode igennem med anklager om snyd og bedrag, og med ham følger en stor ledelsesrokade, der dog ikke har imponeret markedet.

Janssen bruger gylden kupon på psoriasismiddel

Medicinal & Biotek:

Amerikanske Janssen har valgt at bruge en særlig kupon, som man fik fra FDA i 2012, til at fremskynde evalueringen af et nyt antistof til behandling af psoriasis. Sådanne kuponer er tidligere blevet solgt for flere milliarder kroner.

Pfizers version af Amgen-blockbuster får FDA-medvind

Medicinal & Biotek:

Instrukser til en ekspertkomite under FDA, som skal evaluere Pfizers biosimilære version af Amgens milliardsælgende anæmimiddel Epogen, tyder ifølge Endpoints på, at midlet inden længe vil blive godkendt i USA.

ANNONCE
ANNONCE


ANNONCE